Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Status:
Withdrawn
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
Open label single center study for the donation of HCV positive kidneys to HCV negative
recipients with interventional treatment to prevent HCV transmission upon transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Antiviral Agents Elbasvir-grazoprevir drug combination Sofosbuvir